Literature DB >> 32142024

Safety and Tolerability of Repetitive Transcranial Magnetic Stimulation During Pregnancy: A Case Report and Literature Review.

Ugur Damar1,2, Harper Lee Kaye1,2, Nicole A Smith3, Page B Pennell4, Alexander Rotenberg1,2,5.   

Abstract

Patients with neuropsychiatric disease may benefit from repetitive transcranial magnetic stimulation as a nonpharmacologic alternative to relieve symptoms of major depression, obsessive compulsive disorder, and perhaps other syndromes such as epilepsy. We present a case of repetitive transcranial magnetic stimulation treatment as an adjunct therapy for a patient experiencing refractory epileptic seizures during the third trimester of pregnancy. Notably, the patient tolerated repetitive transcranial magnetic stimulation well, without adverse events, and delivered a healthy child. We also summarize the current literature pertaining to therapeutic repetitive transcranial magnetic stimulation use during pregnancy.

Entities:  

Mesh:

Year:  2020        PMID: 32142024     DOI: 10.1097/WNP.0000000000000552

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  2 in total

Review 1.  The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines.

Authors:  Young Sup Woo; Won-Myong Bahk; Jeong Seok Seo; Young-Min Park; Won Kim; Jong-Hyun Jeong; Se-Hoon Shim; Jung Goo Lee; Seung-Ho Jang; Chan-Mo Yang; Sheng-Min Wang; Myung Hun Jung; Hyung Mo Sung; Il Han Choo; Bo-Hyun Yoon; Sang-Yeol Lee; Duk-In Jon; Kyung Joon Min
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-02-28       Impact factor: 2.582

2.  Antidepressant effect r TMS during pregnancy in a case of Major Depression Resistant to Pharmacological Treatment.

Authors:  Isabel Martínez-Gras; Rosa Jurado-Barba; Luis Sánchez-Pastor; Gabriel Rubio; Julio Prieto-Montalvo
Journal:  Actas Esp Psiquiatr       Date:  2021-11-01       Impact factor: 1.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.